At New Day Diagnostics, we create tests that are accurate, easy to use and affordable.
In doing so, we empower people to manage their health on their terms while helping health systems enhance the care they deliver with efficient and accurate tools.
Our commitment is to bring innovative solutions to the healthcare market that improve health outcomes for people around the world.
Important New Tests/Products in Development
Whether it’s at home or in a professional healthcare setting, the benefits of fast, easy, accurate diagnostics aren’t limited to one disease.
That’s why New Day Diagnostics is constantly innovating and adding to our line of testing products:
However, 83% of celiac disease cases are undiagnosed. Our proprietary BIOCARD® Celiac Disease Self-Test uses a blood sample from a finger prick to identify the antibodies associated with celiac disease, allowing patients to mitigate symptoms by shifting to a gluten-free diet.1 Currently available in Europe. Clinical studies in progress for FDA approval.
Respiratory Viruses – Multiplex Test
Our Multiplex BIOCARD® SARS-CoV-2 + Flu A + Flu B + RSV test uses one simple nasal swab and combo test card to identify which disease is present, so patients and providers can make the best care decisions. Clinical studies in progress for FDA approval.
Helicobacter pylori (H. Pylori) – IgG Test
While an infection can be treated with antibiotics, most cases go undiagnosed. Our BIOCARD® Helicobacter pylori IgG Test offers high accuracy and easy detection in just 10 minutes using a single drop of blood. Importantly, antacid medication or antibiotics do not interfere with test results, so patient comfort can be maintained.1 Currently available in Europe. Clinical studies in progress for FDA approval.
Helicobacter pylori (H. Pylori) – Urease Test
The BIOCARD® or Helicobacter pylori Urease Test is an easy tablet test for the rapid detection of the urease activity of biopsy and culture samples.
The tablet is added into water together with the biopsy or culture sample and a positive reaction can mostly be seen within 20-30 minutes. Sensitivity of 95% and specificity of 98.3% exceeds competitive offerings.1 Currently available in Europe. Clinical studies in progress for FDA approval.
Prostate Cancer – ProCare Test
However, current diagnostic testing performs poorly in the early stages of the disease, resulting in needless biopsies and higher healthcare costs. Our non-invasive ProCare test leverages a novel biomarker for the detection of prostate cancer, hopefully allowing for earlier and more effective treatment. In development.
Ovarian Cancer – Ovation Test
Our test, Ovation, showed higher accuracy and specificity compared to the most commonly used test, which we hope will allow earlier diagnosis and improve the chance of survival for patients. In development.
Navroze is Founder and CEO of New Day Diagnostics. Two initial areas of focus of the company are point of care diagnostic markers for Ovarian and Prostate cancer. He is also Founder and CEO of Impact Medical Strategies. Impact Medical Strategies is dedicated to promoting technologies that can solve major global medical unmet needs. Its goal is to make widely applicable devices and health care services sustainable, affordable and accessible to all. Navroze Mehta is also Founder & CEO of Mela Artisans Inc. (www.melaartisans.com). He co-founded Mela with his daughter Sonali Mehta Rao. Mela Artisans blends traditional handcrafting techniques with contemporary design in home and fashion to promote social uplift in artisan communities.
Navroze received an MBA from Syracuse University and a Bachelor of Commerce degree from Sydenham College at the University of Bombay, India. Navroze has been a member of Young Presidents Organization (YPO) for 20 years, is past chair of the Americas Gateway Chapter, and served as Regional Chair of the Economic Development Network. He is also a past member of the Ashoka Support Network (www.ashoka.org), a leader in the field of social entrepreneurship and has invested in several social impact enterprises.
John Keady is President of New Day Diagnostics and Impact Medical Strategies. Serving in this capacity as a Sales, Marketing, and Commercial Operations executive, John brings extensive experience in channel management as well as bringing medical devices to market in multiple manufacturer and distributor leadership positions, both domestically and internationally. Prior to Impact Medical Strategies, John served in a variety of leadership roles at Welch Allyn including Sales, Channel Management, Customer Care, ERP Implementation, Quality and Regulatory, and General Management for businesses in the United States, Europe and Asia Pacific. Most recently he served on the Executive Committee and as Vice President, Sales and Marketing at AliMed developing and executing go-to-market strategies for print, digital, field and inside sales covering Acute Care, Post-Acute Care, Ambulatory Care, Extended Care and Consumer markets in both direct and indirect channels. John received a B.A. from the State University of New York at Geneseo where he was also inducted into the University’s Athletics Hall of Fame for Men’s Ice Hockey. His education also includes the University of Rochester William E. Simon Graduate School of Business, Rochester, NY (Senior Management) and the Macquarie Graduate School of Management, Sydney, Australia (General Management). He is a past member of the Healthcare Industry Distributors Association (www.hida.org) Acute Care Advisory Council, an organization focused on improving and advancing the value of distribution in healthcare.
David Talbert is Vice President of Sales for New Day Diagnostics. He is an accomplished senior-level management executive with a consistent record of delivering exceptional revenue, market share and profit growth with best-in-class consumer product companies. David has over 30 years of experience successfully building and leading sales teams in both large and small consumer product companies. He previously managed sales teams at Vanessa Biotech, Arcadia Consumer Healthcare, Eli Consumer Healthcare, High Ridge Brands, Prestige Brands, J.B. Williams Company and Lederle Consumer Health.
David received a Bachelor of Science degree in Business Management from Christopher Newport University.
Prem Gurnani, Chief Scientific Officer at New Day Diagnostics has over 15 years of expert proficiency in new product development, clinical laboratory setup, operations and management, reimbursement and payor strategy, and health information technology. He started his career at PerkinElmer, Inc., where he was a leading scientist in the Genetic Screening Research and Development group responsible for the successful FDA approval of newborn screening tests. He then moved to Houston, Texas, to start a personalized genetics company, CompanionDx Reference Lab, where he served in various executive positions. Since then, he has helped set up genetics and proteomics clinical labs, and healthcare technology companies, where he held senior executive management positions in operations, technology, strategy development, and R&D.
Prem serves as a consultant for several diagnostics labs and healthcare technology companies. He has authored over 50 publications, including abstracts, posters, presentations, and books. He has also co-authored and served as a co-investigator in multiple grants.
Prem earned his Master of Science degree in Biomedical Engineering from UTSW Medical Center, Dallas/ UT-Arlington, and extended his education with The Wharton Business School and John Hopkins Bloomberg School of Public Health.
Suzanne Lee, Vice President of Operations at New Day Diagnostics, has over 30 years of experience in the healthcare and medical device industry working in hospital administration and operations, healthcare consulting, project management and, most recently, in the development and commercialization of early stage medical devices. Prior to joining New Day Diagnostics, she worked in leadership roles in both large and small healthcare organizations, including Memorial Sloan Kettering Cancer Center, Allegiance Healthcare, Cardinal Health and Oncology Solutions, to develop strategic plans, improve revenue/margin, grow market share, improve quality and create greater operational efficiencies.
Suzanne received a Bachelor of Science degree from Cornell University and a Master of Public Health degree with a concentration in Healthcare Administration from Columbia University. She has recently been certified by The Project Management Institute as a Project Management Professional (PMP).
Kenn Adach, Vice President of Marketing at New Day Diagnostics, is a veteran of the healthcare industry, having a successful sales and marketing career at global leaders in eye care, dental care, infectious disease, skin care, robotics and others. Having been trained in large global organizations (Unilever, Playtex and Bausch + Lomb), he has since applied his expertise in bringing new, innovative and disruptive medical device products to market and expanding existing brands’ market share.
Kenn’s depth of past leadership roles in marketing, sales, innovation/new product development and market research at some of the most respected companies in the country has proven extremely valuable and effective in small to mid-sized firms. He is a master at uncovering the critical insights needed to inform innovative growth strategies that resonate in the marketplace and motivate customers. Kenn leads with passion, creativity, flexibility and a strong motivation to win. He has successfully developed and launched over 50 new products — many of them innovative firsts — and built differentiated strategic marketing plans. His expertise in influencing target audiences spans a variety of HCPs and consumers. Kenn’s track record of driving profitable growth is exemplary as he is highly resourceful, analytical and creative.
Kenn has an undergraduate degree from the University of South Carolina, and an MBA with honors from Rutgers University.
For more information on COVID testing, when to take the tests, and how to use our tests,
please visit our frequently asked questions page. We are passionate about being a resource for your healthcare decisions.
CE Mark for Professional use.
This item is currently not available for sale in the USA until FDA authorized. This page is made available for informational purposes only.
1 In symptomatic patients.